Concepedia

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer

Angeles Alvarez Secord, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert C. Squatrito, Laura J. Havrilesky, Anne C. Gabel, Mark D. Starr, John C. Brady, Andrew B. Nixon,

Gynecologic Oncology · 2019 · 29 citations · 24 references

DOI

Concepts

References

24

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

, , +10

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

Robert A. Burger, Mark F. Brady, Michael A. Bookman et al. · New England Journal of Medicine · 2011 · 2.4K citations · Full text

, , +11

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

, , +11

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al. · Journal of Clinical Oncology · 2014 · 1.6K citations · Full text

, , +17